Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Resolving the fibrotic niche of human liver cirrhosis at single-cell level.

Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, Portman JR, Matchett KP, Brice M, Marwick JA, Taylor RS, Efremova M, Vento-Tormo R, Carragher NO, Kendall TJ, Fallowfield JA, Harrison EM, Mole DJ, Wigmore SJ, Newsome PN, Weston CJ, Iredale JP, Tacke F, Pollard JW, Ponting CP, Marioni JC, Teichmann SA, Henderson NC.

Nature. 2019 Nov;575(7783):512-518. doi: 10.1038/s41586-019-1631-3. Epub 2019 Oct 9.

PMID:
31597160
2.

Safety profile of autologous macrophage therapy for liver cirrhosis.

Moroni F, Dwyer BJ, Graham C, Pass C, Bailey L, Ritchie L, Mitchell D, Glover A, Laurie A, Doig S, Hargreaves E, Fraser AR, Turner ML, Campbell JDM, McGowan NWA, Barry J, Moore JK, Hayes PC, Leeming DJ, Nielsen MJ, Musa K, Fallowfield JA, Forbes SJ.

Nat Med. 2019 Oct;25(10):1560-1565. doi: 10.1038/s41591-019-0599-8. Epub 2019 Oct 7.

PMID:
31591593
3.

Study protocol: HepaT1ca - an observational clinical cohort study to quantify liver health in surgical candidates for liver malignancies.

Mole DJ, Fallowfield JA, Kendall TJ, Welsh F, Semple SI, Bachtiar V, Kelly M, Wigmore SJ, James Garden O, Wilman HR, Banerjee R, Rees M, Brady M.

BMC Cancer. 2018 Sep 12;18(1):890. doi: 10.1186/s12885-018-4737-3.

4.

Non-invasive assessment of liver disease in rats using multiparametric magnetic resonance imaging: a feasibility study.

Hoy AM, McDonald N, Lennen RJ, Milanesi M, Herlihy AH, Kendall TJ, Mungall W, Gyngell M, Banerjee R, Janiczek RL, Murphy PS, Jansen MA, Fallowfield JA.

Biol Open. 2018 Jul 2;7(7). pii: bio033910. doi: 10.1242/bio.033910.

5.

Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study.

McDonald N, Eddowes PJ, Hodson J, Semple SIK, Davies NP, Kelly CJ, Kin S, Phillips M, Herlihy AH, Kendall TJ, Brown RM, Neil DAH, Hübscher SG, Hirschfield GM, Fallowfield JA.

Sci Rep. 2018 Jun 15;8(1):9189. doi: 10.1038/s41598-018-27560-5.

6.

Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease.

Kendall TJ, Dolman GE, Duff CM, Paish EC, Zaitoun A, Irving W, Fallowfield JA, Guha IN.

Histopathology. 2018 Jul;73(1):90-100. doi: 10.1111/his.13499. Epub 2018 Apr 16.

7.

Editorial: getting bullish about portal hypertension-chronic treatment with oral taurine?

Dunne PDJ, Fallowfield JA.

Aliment Pharmacol Ther. 2018 Feb;47(4):533-534. doi: 10.1111/apt.14444. No abstract available.

8.

Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease.

Eddowes PJ, McDonald N, Davies N, Semple SIK, Kendall TJ, Hodson J, Newsome PN, Flintham RB, Wesolowski R, Blake L, Duarte RV, Kelly CJ, Herlihy AH, Kelly MD, Olliff SP, Hübscher SG, Fallowfield JA, Hirschfield GM.

Aliment Pharmacol Ther. 2018 Mar;47(5):631-644. doi: 10.1111/apt.14469. Epub 2017 Dec 22.

9.

Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes.

Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J.

BMJ. 2017 Nov 22;359:j5024. doi: 10.1136/bmj.j5024. Review. Erratum in: BMJ. 2018 Jan 12;360:k194.

10.

In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosis.

McBride A, Hoy AM, Bamford MJ, Mossakowska DE, Ruediger MP, Griggs J, Desai S, Simpson K, Caballero-Hernandez I, Iredale JP, Pell T, Aucott RL, Holmes DS, Webster SP, Fallowfield JA.

Sci Rep. 2017 Sep 7;7(1):10806. doi: 10.1038/s41598-017-10521-9.

11.

Assessment of Haemodynamic Response to Nonselective Beta-Blockers in Portal Hypertension by Phase-Contrast Magnetic Resonance Angiography.

McDonald N, Lilburn DML, Lachlan NJ, Macnaught G, Patel D, Jayaswal ANA, Hayes PC, Semple SI, Fallowfield JA.

Biomed Res Int. 2017;2017:9281450. doi: 10.1155/2017/9281450. Epub 2017 Jun 15.

12.

Editorial: tackling hepatorenal syndrome-terlipressin for all, or time for a stratified approach?

Gifford FJ, Fallowfield JA.

Aliment Pharmacol Ther. 2017 Jul;46(2):193-194. doi: 10.1111/apt.14098. No abstract available.

13.

Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis.

Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J.

BMJ Open. 2017 May 9;7(5):e013739. doi: 10.1136/bmjopen-2016-013739. Review.

14.

Liver Fibrosis: Understanding the Dynamics of Bidirectional Wound Repair to Inform the Design of Markers and Therapies.

Iredale JP, Pellicoro A, Fallowfield JA.

Dig Dis. 2017;35(4):310-313. doi: 10.1159/000456581. Epub 2017 May 3. Review.

15.

Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.

Snowdon VK, Lachlan NJ, Hoy AM, Hadoke PW, Semple SI, Patel D, Mungall W, Kendall TJ, Thomson A, Lennen RJ, Jansen MA, Moran CM, Pellicoro A, Ramachandran P, Shaw I, Aucott RL, Severin T, Saini R, Pak J, Yates D, Dongre N, Duffield JS, Webb DJ, Iredale JP, Hayes PC, Fallowfield JA.

PLoS Med. 2017 Feb 28;14(2):e1002248. doi: 10.1371/journal.pmed.1002248. eCollection 2017 Feb.

16.

Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.

Gifford FJ, Morling JR, Fallowfield JA.

Aliment Pharmacol Ther. 2017 Mar;45(5):593-603. doi: 10.1111/apt.13912. Epub 2017 Jan 4. Review.

17.

Editorial: non-invasive assessment of hepatic fibrosis in alpha-1 antitrypsin deficiency using magnetic resonance elastography.

Hoy AM, Fallowfield JA.

Aliment Pharmacol Ther. 2016 Sep;44(6):644-5. doi: 10.1111/apt.13729. No abstract available.

18.

Editorial: measuring inflammatory and fibrotic components of portal hypertension - a noninvasive hepatic venous pressure gradient?

Snowdon VK, Fallowfield JA.

Aliment Pharmacol Ther. 2016 Jul;44(2):204-5. doi: 10.1111/apt.13667. No abstract available.

19.

Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis.

Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J.

Aliment Pharmacol Ther. 2016 Mar;43(5):562-74. doi: 10.1111/apt.13523. Epub 2016 Jan 25. Review.

20.

Future mechanistic strategies for tackling fibrosis--an unmet need in liver disease.

Fallowfield JA.

Clin Med (Lond). 2015 Dec;15 Suppl 6:s83-7. doi: 10.7861/clinmedicine.15-6-s83. Review.

PMID:
26634688
21.

Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Morling JR, Fallowfield JA, Guha IN, Williamson RM, Ali M, Glancy S, Strachan MW, Price JF.

QJM. 2016 Apr;109(4):249-56. doi: 10.1093/qjmed/hcv191. Epub 2015 Oct 9.

22.

Resolution of liver fibrosis: basic mechanisms and clinical relevance.

Ramachandran P, Iredale JP, Fallowfield JA.

Semin Liver Dis. 2015 May;35(2):119-31. doi: 10.1055/s-0035-1550057. Epub 2015 May 14. Review.

PMID:
25974898
23.

Editorial: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention.

Lachlan NJ, Fallowfield JA.

Aliment Pharmacol Ther. 2015 Jun;41(12):1297. doi: 10.1111/apt.13206. No abstract available.

24.

γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study.

Morling JR, Fallowfield JA, Williamson RM, Robertson CM, Glancy S, Guha IN, Strachan MW, Price JF.

Diabetologia. 2015 Jul;58(7):1484-93. doi: 10.1007/s00125-015-3575-y. Epub 2015 Mar 29.

25.

Liver fibrosis and repair: immune regulation of wound healing in a solid organ.

Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA.

Nat Rev Immunol. 2014 Mar;14(3):181-94. doi: 10.1038/nri3623. Review.

PMID:
24566915
26.

Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study.

Morling JR, Fallowfield JA, Guha IN, Nee LD, Glancy S, Williamson RM, Robertson CM, Strachan MW, Price JF; Edinburgh Type 2 Diabetes Study investigators.

J Hepatol. 2014 Feb;60(2):384-91. Epub 2013 Oct 26.

27.

Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study.

Morling JR, Fallowfield JA, Williamson RM, Nee LD, Jackson AP, Glancy S, Reynolds RM, Hayes PC, Guha IN, Strachan MW, Price JF.

Liver Int. 2014 Sep;34(8):1267-77. doi: 10.1111/liv.12385. Epub 2013 Dec 3.

28.

Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo.

Fallowfield JA, Hayden AL, Snowdon VK, Aucott RL, Stutchfield BM, Mole DJ, Pellicoro A, Gordon-Walker TT, Henke A, Schrader J, Trivedi PJ, Princivalle M, Forbes SJ, Collins JE, Iredale JP.

Hepatology. 2014 Apr;59(4):1492-504. doi: 10.1002/hep.26627. Epub 2014 Mar 3.

PMID:
23873655
29.

Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis.

Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, Hartland SN, Snowdon VK, Cappon A, Gordon-Walker TT, Williams MJ, Dunbar DR, Manning JR, van Rooijen N, Fallowfield JA, Forbes SJ, Iredale JP.

Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):E3186-95. doi: 10.1073/pnas.1119964109. Epub 2012 Oct 24.

30.

Noninvasive evaluation of portal hypertension: emerging tools and techniques.

Snowdon VK, Guha N, Fallowfield JA.

Int J Hepatol. 2012;2012:691089. doi: 10.1155/2012/691089. Epub 2012 Jun 7.

31.

Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis.

Pellicoro A, Aucott RL, Ramachandran P, Robson AJ, Fallowfield JA, Snowdon VK, Hartland SN, Vernon M, Duffield JS, Benyon RC, Forbes SJ, Iredale JP.

Hepatology. 2012 Jun;55(6):1965-75. doi: 10.1002/hep.25567. Epub 2012 Apr 18.

PMID:
22223197
32.

Models and mechanisms of fibrosis resolution.

Snowdon VK, Fallowfield JA.

Alcohol Clin Exp Res. 2011 May;35(5):794-9. doi: 10.1111/j.1530-0277.2010.01400.x. Epub 2011 Feb 1. Review.

PMID:
21284668
33.

Therapeutic targets in liver fibrosis.

Fallowfield JA.

Am J Physiol Gastrointest Liver Physiol. 2011 May;300(5):G709-15. doi: 10.1152/ajpgi.00451.2010. Epub 2011 Jan 13. Review.

34.

Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response.

Kallis YN, Robson AJ, Fallowfield JA, Thomas HC, Alison MR, Wright NA, Goldin RD, Iredale JP, Forbes SJ.

Gut. 2011 Apr;60(4):525-33. doi: 10.1136/gut.2010.224436. Epub 2010 Nov 23.

PMID:
21106552
35.

Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis.

Fallowfield JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, Duffield JS, Iredale JP.

J Immunol. 2007 Apr 15;178(8):5288-95.

36.

Reversal of fibrosis: no longer a pipe dream?

Fallowfield JA, Kendall TJ, Iredale JP.

Clin Liver Dis. 2006 Aug;10(3):481-97, viii. Review.

PMID:
17162224
37.

Targeted treatments for cirrhosis.

Fallowfield JA, Iredale JP.

Expert Opin Ther Targets. 2004 Oct;8(5):423-35. Review.

PMID:
15469393
38.

Reversal of liver fibrosis and cirrhosis--an emerging reality.

Fallowfield JA, Iredale JP.

Scott Med J. 2004 Feb;49(1):3-6. Review. No abstract available.

PMID:
15012043

Supplemental Content

Loading ...
Support Center